Iloprost Zentiva (Iloprost)

Iloprost mimics the natural prostacyclin molecule and binds to IP receptors on pulmonary vascular smooth‑muscle cells. This activates adenylate cyclase, raising intracellular cyclic AMP levels, which causes vasodilation, inhibits platelet aggregation, and suppresses smooth‑muscle proliferation. The combined actions reduce pulmonary arterial pressure and improve oxygen delivery.

The exact dosing regimen for Iloprost Zentiva is individualized by the prescribing physician based on disease severity, response, and tolerability. In clinical practice the inhalation solution is commonly administered 2 to 6 times per day, with each session lasting a few minutes using a certified nebulizer. Patients should follow the specific instructions provided by their healthcare professional.

Safety data for Iloprost during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their physician.

To place an order, submit an enquiry on the Iloprost Zentiva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Iloprost is an inhaled prostacyclin analogue, offering targeted pulmonary delivery and rapid onset, whereas agents such as epoprostenol are administered intravenously and treprostinil can be given subcutaneously, orally, or inhaled. Compared with oral endothelin receptor antagonists, Iloprost provides direct vasodilation but requires patient‑operated nebulization, making it suitable for patients who prefer inhaled therapy or need combination treatment.

The inhalation solution should be stored at room temperature, preferably below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight and extreme temperatures. Do not freeze the solution, and keep it out of reach of children. Once opened, use according to the manufacturer’s stability guidelines.

Iloprost Zentiva is supplied as a sterile solution for nebulization. The patient uses a compatible ultrasonic or jet nebulizer, inhaling the mist over a few minutes. Dosing frequency and duration are prescribed by the clinician. Proper cleaning of the nebulizer device and adherence to inhalation technique are essential for optimal drug delivery.

The most critical adverse events include marked hypotension, which can lead to dizziness or syncope, severe bronchospasm causing respiratory distress, pulmonary edema, and bleeding complications such as hemoptysis. Patients should be educated to seek immediate medical attention if they experience sudden shortness of breath, chest pain, or unexplained bleeding.

Iloprost is contraindicated in individuals with known hypersensitivity to iloprost or any component of the formulation. It should also be avoided in patients with severe hypotension, recent myocardial infarction (within the past 30 days), active uncontrolled bleeding, or severe pulmonary infection. Clinicians must assess each patient’s medical history before initiating therapy.